| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | KITE PHARMA INCORPORATED | 2,358,084 | 105,736,000 | 48.63% | ||
| 2 | COSTAR GROUP | 195,117 | 36,778,000 | 16.91% | ||
| 3 | Nantkwest Inc | 4,485,495 | 25,657,000 | 11.80% | ||
| 4 | SORRENTO THERAPEUTICS INC COM NEW | 2,799,790 | 13,719,000 | 6.31% | ||
| 5 | MIMEDX GROUP INC COM | 1,080,365 | 9,572,000 | 4.40% | ||
| 6 | BARCLAYS BK PLC | 320,600 | 8,179,000 | 3.76% | ||
| 7 | LPL FINL HLDGS INC COM | 206,647 | 7,276,000 | 3.35% | ||
| 8 | COMMUNICATIONS SALES&LEAS IN | 163,000 | 4,142,000 | 1.90% | ||
| 9 | ISHARES TR | 10,400 | 2,760,000 | 1.27% | ||
| 10 | NANTHEALTH INC | 238,828 | 2,374,000 | 1.09% | ||
| 11 | EDITAS MEDICINE INCORPORATED | 41,324 | 671,000 | 0.31% | ||
| 12 | ISHARES TR | 1,719 | 456,000 | 0.21% | ||
| 13 | INTELLIA THERAPEUTICS INC | 3,542 | 46,000 | 0.02% | ||
| 14 | ADVERUM BIOTECHNOLOGIES INC | 15,000 | 44,000 | 0.02% | ||
| 15 | GENERAL MTRS CO | 800 | 28,000 | 0.01% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0000903423-17-000115, filed 2017.02.14).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
